norfloxacin has been researched along with theophylline in 53 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (24.53) | 18.7374 |
| 1990's | 6 (11.32) | 18.2507 |
| 2000's | 6 (11.32) | 29.6817 |
| 2010's | 28 (52.83) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cortijo, J; Gálvez, J; García-Domenech, R; Morcillo, E; Ríos-Santamarina, I; Santamaria, P | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Akamatsu, M; Fujikawa, M; Nakao, K; Shimizu, R | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Akamatsu, M | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Deng, Y; Li, Y; Liu, Q; Qiang, X; Sang, Z; Tan, Z; Xiao, G | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Deng, Y; Li, Y; Luo, L; Qiang, X; Tan, Z; Xiao, G | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Sang, Z; Su, F; Xiao, G; Yang, X; Zheng, Y | 1 |
| Ai, J; Deng, Y; Li, Y; Liu, Q; Luo, L; Qiang, X; Tan, Z; Xiao, G; Yang, X | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Sang, Z; Su, F; Xiao, G; Xu, R; Yang, X; Zheng, Y | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Tan, Z; Xu, R; Yang, X; Zheng, Y | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Song, Q; Tan, Z; Xiao, G; Xu, R; Yang, X | 1 |
| Bai, P; Leng, C; Li, X; Liu, W; Ma, Q; Pan, W; Sang, Z; Tan, Z; Wang, K; Xu, Q; Yang, Y; Yu, L | 1 |
| Liu, W; Ma, Q; Pan, W; Sang, Z; Wang, K; Yu, L | 1 |
| Han, X; Liu, W; Ma, Q; Sang, Z; Wang, H; Wang, K; Ye, M; Yu, L | 2 |
| Cao, Z; Deng, Y; Li, Y; Liu, H; Qiang, X; Song, Q; Tan, Z; Xu, R; Yang, J; Zhang, X | 1 |
| Deng, Y; Li, Y; Liu, H; Song, Q; Tan, Z; Xiao, G; Xu, R; Yang, Z; Zhang, X; Zheng, Y | 1 |
| An, Q; Deng, Y; Liu, P; Luo, Y; Sang, Z; Tang, Y; Wang, T; Yang, T; Yang, Y; Zhang, T | 1 |
| Cao, Z; Deng, Y; Li, Y; Liu, H; Qiang, X; Song, Q; Tan, Z; Tian, C; Yang, Z | 1 |
| Deng, Y; He, Y; Li, W; Liu, H; Qiang, X; Song, Q; Tan, Z; Ye, C | 1 |
| Liu, W; Sang, Z; Shi, J; Tan, Z; Wang, K | 1 |
| Liu, W; Sang, Z; Shi, J; Tan, Z; Wang, K; Zhang, P | 1 |
| Fan, X; Liu, W; Sang, Z; Shi, J; Wang, K; Yang, D; Zhang, P; Zhang, Z; Zhu, G | 1 |
| Bai, P; Cheng, X; Cheng, Y; Lu, X; Sang, Z; Shi, J; Wang, K; Yang, J; Zhang, P; Zhang, Q; Zheng, C | 1 |
| Schwark, WS; Vancutsem, PM | 1 |
| Guzelian, PS; Hunt, C; Karnes, HT; Polk, RE; Sarkar, M | 1 |
| Nakanishi, S; Okuno, H | 1 |
| Davis, RL; Gallegos, J; Kelly, HW; Quenzer, RW; Standefer, J; Steinberg, B | 1 |
| Goto, M; Kawakatsu, K; Sano, M; Takeyama, M; Yamamoto, I; Yamashina, H | 1 |
| Adair, CG; Casabar, E; Kasik, JE; Lettieri, J; Prince, RA; Wexler, DB | 1 |
| Clark, J; Green, L | 1 |
| Beer, C; Harder, S; Papenburg, A; Shah, PM; Staib, AH; Stille, W | 1 |
| Goto, M; Kawakatsu, K; Ohkita, C; Sano, M; Takeyama, M; Yamamoto, I; Yamashina, H | 1 |
| Beckman, HB; Bowles, SK; Edwards, DJ; Popovski, Z; Rybak, MJ | 1 |
| Dales, RE; Ho, G; Tierney, MG | 1 |
| Goto, M; Sano, M; Ueda, J; Yamamoto, I; Yamashina, H; Yoshikawa, E | 1 |
| Kawane, H; Niki, Y; Soejima, R; Sumi, M; Umeki, S | 1 |
| Baars, AM; van Herwaarden, CL; Vree, TB; Wijnands, WJ | 2 |
| Aizawa, T; Fujimoto, Y; Mue, S; Ohtsu, H; Sakai, K; Satoh, K; Takishima, T; Tamura, G | 1 |
| Aarons, L; Davis, JD; Houston, JB | 2 |
| Bouquet, S; Cadart, M; Couet, W; Marchand, S; Pariat, C | 1 |
| Bois, FY; Brochot, C; Couet, W; Gelman, A; Marchand, S | 1 |
| Abd El-Aty, AM; Kubota, R; Regmi, NL; Shimoda, M; Tomita, A | 1 |
| Homma, M; Kobayashi, D; Kobayashi, T; Kohda, Y; Momo, K | 1 |
1 review(s) available for norfloxacin and theophylline
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 trial(s) available for norfloxacin and theophylline
| Article | Year |
|---|---|
Effect of norfloxacin on theophylline metabolism.
Topics: Adult; Drug Interactions; Female; Humans; Male; Norfloxacin; Theophylline | 1989 |
Effect of quinolone antimicrobials on theophylline pharmacokinetics.
Topics: Adult; Ciprofloxacin; Half-Life; Humans; Male; Metabolic Clearance Rate; Nalidixic Acid; Norfloxacin; Random Allocation; Theophylline | 1989 |
4-quinolones inhibit biotransformation of caffeine.
Topics: Adult; Biotransformation; Caffeine; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Interactions; Enoxacin; Humans; Male; Molecular Structure; Norfloxacin; Ofloxacin; Pipemidic Acid; Quinolones; Random Allocation; Theophylline | 1988 |
Effect of norfloxacin on theophylline pharmacokinetics at steady state.
Topics: Administration, Oral; Adult; Drug Interactions; Humans; Male; Norfloxacin; Random Allocation; Theophylline | 1988 |
48 other study(ies) available for norfloxacin and theophylline
| Article | Year |
|---|---|
New bronchodilators selected by molecular topology.
Topics: Animals; Bronchodilator Agents; Discriminant Analysis; Female; Guinea Pigs; In Vitro Techniques; Male; Muscle Relaxation; Structure-Activity Relationship; Trachea | 1998 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
QSAR study on permeability of hydrophobic compounds with artificial membranes.
Topics: Biological Transport; Caco-2 Cells; Drug Evaluation, Preclinical; Humans; Hydrophobic and Hydrophilic Interactions; Membranes, Artificial; Permeability; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship | 2007 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Importance of physicochemical properties for the design of new pesticides.
Topics: Anabasine; Animals; Biological Availability; Cell Membrane Permeability; Chemical Phenomena; Drug Design; Humans; Imidazoles; Insecticides; Neonicotinoids; Nitro Compounds; Pesticides; Quantitative Structure-Activity Relationship; Receptors, Nicotinic | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Apigenin; Blood-Brain Barrier; Butyrylcholinesterase; Carbamates; Cell Line; Chelating Agents; Cholinesterase Inhibitors; Cognition; Glucuronates; Humans; Mice; Molecular Docking Simulation; Neuroprotective Agents; Rats | 2015 |
Synthesis and evaluation of 4-hydroxyl aurone derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Benzofurans; Blood-Brain Barrier; Chelating Agents; Copper; Humans; Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Peptide Fragments; Protein Aggregates; Swine | 2016 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Isoflavones; Mannich Bases; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship | 2017 |
Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggragation and neuroprotective properties for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; Drug Design; Electrophorus; Humans; Mannich Bases; Neuroprotective Agents; PC12 Cells; Rats | 2017 |
Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Chalcones; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Rivastigmine; Structure-Activity Relationship; Swine | 2017 |
DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Antipyrine; Benzofurans; Binding Sites; Blood-Brain Barrier; Edaravone; Humans; Hydrogen Bonding; Inhibitory Concentration 50; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Protein Binding; Protein Structure, Tertiary | 2017 |
Multifunctional thioxanthone derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Cell Line; Cholinesterase Inhibitors; Humans; Kinetics; Models, Molecular; Monoamine Oxidase Inhibitors; Thioxanthenes; Xanthones | 2017 |
Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Coumaric Acids; Drug Design; Eels; Humans; Memory Disorders; Mice; PC12 Cells; Rats | 2017 |
Design, synthesis and biological evaluation of 3,4-dihydro-2(1H)-quinoline-O-alkylamine derivatives as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Drug Design; Electrophorus; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quinolines; Swine | 2017 |
Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amines; Binding Sites; Blood-Brain Barrier; Cell Line, Tumor; Cell Survival; Cholinesterase Inhibitors; Cholinesterases; Drug Design; Humans; Inhibitory Concentration 50; Kinetics; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Phthalimides; Protein Structure, Tertiary; Structure-Activity Relationship | 2017 |
Design, synthesis and biological evaluation of 2-acetyl-5-O-(amino-alkyl)phenol derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Benzophenones; Binding Sites; Blood-Brain Barrier; Cell Survival; Cholinesterase Inhibitors; Drug Design; Humans; Hydrogen Peroxide; Inhibitory Concentration 50; Molecular Docking Simulation; Monoamine Oxidase; Neuroprotective Agents; PC12 Cells; Permeability; Phenols; Piperazines; Protein Structure, Tertiary; Rats; Structure-Activity Relationship | 2017 |
Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Line; Cell Survival; Chalcones; Chelating Agents; Copper; Drug Design; Flurbiprofen; Humans; Lipopolysaccharides; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nitric Oxide; Peptide Fragments; Recombinant Proteins; Structure-Activity Relationship | 2018 |
Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Benzylamines; Blood-Brain Barrier; Cholinesterase Inhibitors; Drug Design; Humans; Kinetics; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Permeability; Protein Aggregates; Recombinant Proteins; Structure-Activity Relationship; Thiazoles | 2018 |
Discovery of novel anti-tuberculosis agents with pyrrolo[1,2-a]quinoxaline-based scaffold.
Topics: Antineoplastic Agents; Antitubercular Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Pyrroles; Quinoxalines; Structure-Activity Relationship | 2018 |
Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Butyrylcholinesterase; Chelating Agents; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Discovery; Humans; Models, Molecular; Molecular Structure; Peptide Fragments; Phthalimides; Protein Aggregates; Structure-Activity Relationship | 2018 |
Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Cell Line; Cholinesterase Inhibitors; Drug Design; Drug Discovery; Electrophorus; Flurbiprofen; Humans; Mannich Bases; Molecular Docking Simulation; Peptide Fragments; Protein Aggregates; Rats; Swine | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Chalcones; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Eels; Female; Horses; Humans; Male; Maze Learning; Mice; Mice, Inbred Strains; Models, Molecular; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Peptide Fragments; Protein Aggregates; Rats; Structure-Activity Relationship | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Chalcone; Cholinesterase Inhibitors; Drug Design; Eels; Horses; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Peptide Fragments; Protein Aggregates | 2019 |
The development of 2-acetylphenol-donepezil hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cholinesterases; Donepezil; Drug Design; Drug Development; Humans; Kinetics; Models, Molecular; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship | 2019 |
Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Biological Transport; Blood-Brain Barrier; Butyrylcholinesterase; Chalcones; Chelating Agents; Cholinesterase Inhibitors; Coordination Complexes; Copper; Drug Design; Female; Humans; Male; Memory Disorders; Mice; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Protein Binding; Scopolamine; Structure-Activity Relationship | 2019 |
Effects of fluoroquinolone antimicrobials alone and in conjunction with theophylline on seizures in amygdaloid kindled rats. Mechanistic and pharmacokinetic study.
Topics: 2-Chloroadenosine; Amygdala; Animals; Anti-Infective Agents; Chromatography, High Pressure Liquid; Diazepam; Dose-Response Relationship, Drug; Electrodes, Implanted; Enrofloxacin; Female; Fluoroquinolones; Kindling, Neurologic; Norfloxacin; Quinolones; Rats; Rats, Sprague-Dawley; Seizures; Theophylline | 1992 |
In vitro effect of fluoroquinolones on theophylline metabolism in human liver microsomes.
Topics: Biotransformation; Chromatography, High Pressure Liquid; Ciprofloxacin; Drug Interactions; Enoxacin; Humans; Hydroxylation; Microsomes, Liver; Norfloxacin; Theophylline; Uric Acid; Xanthines | 1990 |
Comparison of inhibitory effects of new quinolones on drug metabolizing activity in the liver.
Topics: Acetaminophen; Animals; Anti-Infective Agents; Enoxacin; Glutathione; Liver; Liver Function Tests; Male; Microsomes, Liver; Mixed Function Oxygenases; Norfloxacin; Ofloxacin; Rats; Theophylline | 1990 |
Inhibitory effect of enoxacin, ofloxacin and norfloxacin on renal excretion of theophylline in humans.
Topics: Adult; Drug Interactions; Enoxacin; Female; Humans; Kidney; Male; Metabolic Clearance Rate; Norfloxacin; Ofloxacin; Theophylline | 1989 |
Fluoroquinolones and theophylline toxicity: norfloxacin.
Topics: Aged; Female; Humans; Norfloxacin; Theophylline | 1989 |
Effects of enoxacin, ofloxacin and norfloxacin on theophylline disposition in humans.
Topics: 17-Hydroxycorticosteroids; Adult; Aminophylline; Enoxacin; Female; Humans; Hydrocortisone; Male; Metabolic Clearance Rate; Norfloxacin; Ofloxacin; Theophylline | 1988 |
Evaluation of the effect of norfloxacin on the pharmacokinetics of theophylline.
Topics: Adult; Aminophylline; Drug Interactions; Female; Humans; Male; Mathematics; Norfloxacin; Statistics as Topic; Theophylline | 1988 |
Comparative pharmacokinetics of theophylline following two fluoroquinolones co-administration.
Topics: Adult; Anti-Infective Agents; Drug Interactions; Female; Humans; Kinetics; Male; Norfloxacin; Ofloxacin; Oxazines; Theophylline | 1987 |
New synthetic quinolone antibacterial agents and serum concentration of theophylline.
Topics: Adult; Anti-Infective Agents; Chemical Phenomena; Chemistry; Ciprofloxacin; Drug Administration Schedule; Drug Therapy, Combination; Humans; Male; Norfloxacin; Ofloxacin; Oxazines; Pefloxacin; Pipemidic Acid; Theophylline | 1987 |
Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintenance treatment with theophylline.
Topics: Aged; Anti-Infective Agents; Ciprofloxacin; Drug Interactions; Enoxacin; Female; Humans; Male; Middle Aged; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Pefloxacin; Quinolines; Theophylline | 1987 |
The influence of the 4-quinolones ciprofloxacin, pefloxacin and ofloxacin on the elimination of theophylline.
Topics: Aged; Anti-Infective Agents; Ciprofloxacin; Female; Humans; Lung Diseases, Obstructive; Male; Metabolic Clearance Rate; Middle Aged; Norfloxacin; Ofloxacin; Oxazines; Pefloxacin; Quinolines; Theophylline | 1987 |
[Norfloxacin does not raise theophylline concentrations in plasma].
Topics: Aged; Drug Interactions; Drug Therapy, Combination; Female; Humans; Lung Diseases, Obstructive; Male; Middle Aged; Norfloxacin; Theophylline | 1987 |
Effect of norfloxacin on theophylline disposition: a comparison with other fluoroquinolones.
Topics: Animals; Anti-Infective Agents; Chromatography, High Pressure Liquid; Drug Interactions; Infusions, Intravenous; Liver; Male; Norfloxacin; Rats; Rats, Sprague-Dawley; Theophylline; Tissue Distribution | 1995 |
Simultaneous assay of fluoroquinolones and theophylline in plasma by high-performance liquid chromatography.
Topics: Animals; Chromatography, High Pressure Liquid; Ciprofloxacin; Enoxacin; Male; Norfloxacin; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Theophylline | 1993 |
Ignoring pharmacokinetics may lead to isoboles misinterpretation: illustration with the norfloxacin-theophylline convulsant interaction in rats.
Topics: Algorithms; Animals; Anti-Infective Agents; Bronchodilator Agents; Chromatography, High Pressure Liquid; Drug Interactions; Male; Models, Theoretical; Norfloxacin; Rats; Rats, Sprague-Dawley; Seizures; Theophylline | 2002 |
Extension of the isobolographic approach to interactions studies between more than two drugs: illustration with the convulsant interaction between pefloxacin, norfloxacin, and theophylline in rats.
Topics: Animals; Drug Interactions; Male; Norfloxacin; Pefloxacin; Rats; Rats, Sprague-Dawley; Seizures; Theophylline | 2004 |
Effect of ofloxacin on theophylline pharmacokinetics at clinical dosage in dogs.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Area Under Curve; Dogs; Drug Interactions; Female; Half-Life; Injections, Intravenous; Metabolic Clearance Rate; Norfloxacin; Ofloxacin; Protein Binding; Theophylline; Vasodilator Agents | 2006 |
A simple chromatographic method for determining norfloxacin and enoxacin in pharmacokinetic study assessing CYP1A2 inhibition.
Topics: Adult; Caffeine; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Enoxacin; Humans; Male; Norfloxacin; Reproducibility of Results; Sensitivity and Specificity; Theophylline | 2011 |